"Antibodies, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
| Descriptor ID |
D000912
|
| MeSH Number(s) |
D12.776.124.486.485.114.240 D12.776.124.790.651.114.240 D12.776.377.715.548.114.240
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Neoplasm".
This graph shows the total number of publications written about "Antibodies, Neoplasm" by people in this website by year, and whether "Antibodies, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2020 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Neoplasm" by people in Profiles.
-
Raibagkar P, Ho D, Gunturu KS, Srinivasan J. Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: Case report and review of literature. J Neuroimmunol. 2020 04 15; 341:577184.
-
Lemke-Miltner CD, Blackwell SE, Yin C, Krug AE, Morris AJ, Krieg AM, Weiner GJ. Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization. J Immunol. 2020 03 01; 204(5):1386-1394.
-
Zhang H, Liu L, Yu D, Kandimalla ER, Sun HB, Agrawal S, Guha C. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy. PLoS One. 2012; 7(5):e38111.
-
Liu G, Dou S, Chen X, Chen L, Liu X, Rusckowski M, Hnatowich DJ. Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted. Cancer Biother Radiopharm. 2010 Dec; 25(6):757-62.
-
Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Cancer Biol Ther. 2010 Oct 15; 10(8):767-74.
-
Liu G, Dou S, Pretorius PH, Liu X, Chen L, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using MORF conjugated CC49 antibody and radiolabeled complimentary cMORF effector. Q J Nucl Med Mol Imaging. 2010 Jun; 54(3):333-40.
-
Liu G, Dou S, Liang M, Chen X, Rusckowski M, Hnatowich DJ. The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size. Eur J Cancer. 2009 Nov; 45(17):3098-103.
-
Chen X, Dou S, Liu G, Liu X, Wang Y, Chen L, Rusckowski M, Hnatowich DJ. Synthesis and in vitro characterization of a dendrimer-MORF conjugate for amplification pretargeting. Bioconjug Chem. 2008 Aug; 19(8):1518-25.
-
Liu G, Dou S, Rusckowski M, Hnatowich DJ. An experimental and theoretical evaluation of the influence of pretargeting antibody on the tumor accumulation of effector. Mol Cancer Ther. 2008 May; 7(5):1025-32.
-
Wright SE, Rewers-Felkins KA, Quinlin IS, Fogler WE, Phillips CA, Townsend M, Robinson W, Philip R. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol Invest. 2008; 37(3):215-25.